Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by CENTRAL TRUST Co

CENTRAL TRUST Co lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 954 shares of the company’s stock after selling 198 shares during the quarter. CENTRAL TRUST Co’s holdings in Medpace were worth $292,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Wellington Management Group LLP increased its position in Medpace by 312.6% during the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after purchasing an additional 319,210 shares in the last quarter. Wasatch Advisors Inc. increased its position in Medpace by 12.1% during the 1st quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock worth $446,338,000 after purchasing an additional 294,103 shares in the last quarter. Invesco Ltd. increased its position in Medpace by 67.6% during the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after purchasing an additional 246,775 shares in the last quarter. Virginia Retirement Systems ET AL acquired a new stake in Medpace during the 2nd quarter worth approximately $54,927,000. Finally, Millennium Management LLC increased its position in Medpace by 102.3% during the 4th quarter. Millennium Management LLC now owns 450,938 shares of the company’s stock worth $95,784,000 after purchasing an additional 228,001 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Activity

In other news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The disclosure for this sale can be found here. In the last three months, insiders sold 189,340 shares of company stock worth $76,651,647. 25.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on MEDP shares. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price for the company. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, March 23rd. Robert W. Baird increased their price objective on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research report on Wednesday, February 14th. Finally, UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and increased their price objective for the company from $282.00 to $452.00 in a research report on Thursday, February 15th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $382.00.

Medpace Trading Up 2.0 %

Medpace stock opened at $408.71 on Tuesday. The stock has a market cap of $12.66 billion, a P/E ratio of 46.03, a price-to-earnings-growth ratio of 2.12 and a beta of 1.38. The stock has a 50 day moving average of $378.34 and a 200-day moving average of $310.66. Medpace Holdings, Inc. has a 52 week low of $185.43 and a 52 week high of $419.42.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 12th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.22 by $0.24. The company had revenue of $498.40 million during the quarter, compared to analysts’ expectations of $498.72 million. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The business’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.12 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 10.53 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.